Epitalon is a synthetic tetrapeptide derived from work on pineal gland extracts, developed by a single research group in St Petersburg. The claims attached to it are among the largest made for anything in this catalogue: telomerase activation, lifespan extension, restoration of circadian and endocrine function with age.

The evidence base is among the smallest. Almost the entire literature originates from the group that developed it, spans several decades, and has essentially no independent replication. That combination should govern how the claims are read.

The proposed mechanism is that this short peptide interacts with DNA to influence gene expression, including activation of the telomerase catalytic subunit, restoring telomere length in somatic cells.

This is a large mechanistic claim for a four-residue peptide, and the proposed mode of action, direct sequence-specific DNA interaction by a tetrapeptide, is not an established mechanism in molecular biology. It has not been independently characterised.

It is also worth noting that telomerase activation is not straightforwardly desirable. Telomerase reactivation is a feature of the large majority of human cancers, and the replicative limit it circumvents is a tumour-suppressive mechanism.

Mechanistic, and from one source. Reported findings include increased telomerase activity in cell culture, lifespan extension in rodents and other model organisms, and long-running human observational work reporting reduced mortality in an elderly cohort.

Independent replication is essentially absent. The human work is not randomised, is decades old, and comes from the same group. In a literature this concentrated, consistency of results carries little evidential weight, for the same reason it does not in the BPC-157 entry.

Nothing here meets the standard that would be applied to any other compound making a longevity claim.

Effectively no human safety data by modern standards. No characterised toxicology, no immunogenicity data, no long-term controlled follow-up.

The mechanistic concern is the mechanism itself. If the telomerase claim were true, then sustained systemic telomerase activation removes a barrier to unlimited cell replication, which is a step most cancers have to take. Either the claim is not true, in which case the compound does not do what it says, or it is true, in which case it warrants oncological safety data that does not exist. Both branches argue for caution.

Not approved anywhere. Sold as a research chemical.